Last 35 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.00 | 1.89 | 117.64 | 91.13 | 2.56 | 11.43 | 41.21 | 14.72 | 65.18 | 145.85 | 28.10 | 13.57 | 35.97 | 37.14 | 16.90 | 32.58 | 69.03 | 56.77 | 28.41 | 84.14 | 116.18 |
| — | -83.5% | +185.5% | +519.1% | -96.1% | -92.2% | +46.6% | +8.5% | +81.2% | +292.7% | +66.3% | -58.4% | -47.9% | -34.6% | -40.5% | -61.3% | -40.6% | -5.5% | -72.2% | -7.8% | +373.1% | |
| P/B Ratio | 0.41 | 0.51 | 0.58 | 0.58 | 0.81 | 0.87 | 0.72 | 0.79 | 1.22 | 1.88 | 1.20 | 2.98 | 2.07 | 1.91 | 3.50 | 2.62 | 3.25 | 2.38 | 1.60 | 3.93 | 5.06 |
| — | -41.2% | -19.4% | -26.5% | -34.0% | -53.8% | -40.3% | -73.3% | -41.0% | -1.7% | -65.6% | +13.4% | -36.3% | -19.9% | +119.1% | -33.3% | -35.8% | -60.9% | -68.9% | -15.3% | +27.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 5.70 | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -2332.5% | -474.0% | -1412.2% | -1605.8% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | 0.0% | +104.3% | +121.1% | +107.1% | +106.2% | -2432.5% | -574.0% | -1512.2% | -1705.8% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +162.0% | |
| Operating Margin | -341.3% | -39.6% | -8673.9% | -7394.5% | -51.4% | -558.6% | -2965.8% | -703.7% | -1824.8% | -2385.9% | -498.3% | -162.4% | -1017.4% | -949.1% | -378.3% | -853.8% | -1011.3% | -978.9% | -623.6% | -709.4% | -478.0% |
| — | +92.9% | -192.5% | -950.9% | +97.2% | +76.6% | -495.2% | -333.3% | -79.4% | -151.4% | -31.7% | +81.0% | -0.6% | +3.0% | +39.3% | -20.4% | -111.6% | -196.7% | +35.6% | +20.0% | -7.8% | |
| Net Margin | -301.7% | -30.8% | -8002.1% | -6857.4% | -42.0% | -503.7% | -2703.8% | -608.9% | -1398.4% | -1898.4% | -425.3% | -136.0% | -921.0% | -932.3% | -373.8% | -797.9% | -941.2% | -932.5% | -612.8% | -714.1% | -478.3% |
| — | +93.9% | -196.0% | -1026.1% | +97.0% | +73.5% | -535.8% | -347.7% | -51.8% | -103.6% | -13.8% | +83.0% | +2.1% | +0.0% | +39.0% | -11.7% | -96.8% | -175.3% | +38.9% | +20.3% | -5.6% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -31.2% | -2.1% | -9.5% | -10.4% | -3.3% | -9.2% | -11.2% | -7.9% | -6.4% | -6.0% | -6.5% | -7.3% | -12.5% | -15.7% | -18.4% | -15.2% | -10.7% | -9.4% | -8.4% | -8.1% | -7.0% |
| — | +77.5% | +15.6% | -31.9% | +48.6% | -54.1% | -73.1% | -8.4% | +48.8% | +62.0% | +64.8% | +51.9% | -16.6% | -66.3% | -120.0% | -86.5% | -53.4% | -0.6% | +33.7% | +40.2% | +59.0% | |
| ROA | -26.2% | -1.8% | -8.0% | -8.9% | -2.7% | -7.4% | -9.2% | -6.6% | -5.3% | -4.9% | -5.0% | -4.7% | -8.0% | -9.1% | -9.6% | -9.3% | -7.2% | -6.6% | -5.9% | -5.9% | -4.7% |
| — | +75.9% | +13.1% | -34.5% | +48.7% | -49.7% | -85.4% | -42.0% | +33.3% | +45.8% | +48.6% | +50.0% | -9.9% | -38.9% | -62.8% | -58.6% | -52.8% | -13.6% | +25.6% | +30.2% | +55.0% | |
| ROIC | — | -31.9% | -340.1% | -1105.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 | 0.12 | 0.12 | 0.11 | 0.21 | 0.20 | 0.16 | 0.15 | 0.15 | 0.14 | 0.13 |
| — | +202.3% | +124.6% | +124.7% | +130.8% | -30.4% | -75.6% | -90.0% | -90.1% | -87.9% | -77.1% | -39.5% | -26.0% | -27.8% | +46.2% | +42.6% | +27.8% | -21.4% | -37.4% | -39.0% | -22.5% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 11.98 | 12.09 | 12.08 | 12.66 | 11.98 | 10.66 | 10.39 | 14.86 | 13.81 | 17.13 | 14.77 | 10.42 | 8.08 | 8.65 | 5.65 | 7.19 | 6.92 | 9.18 | 9.88 | 12.14 | 12.65 |
| — | +13.4% | +16.2% | -14.8% | -13.2% | -37.7% | -29.7% | +42.6% | +70.9% | +98.1% | +161.4% | +44.9% | +16.7% | -5.8% | -42.8% | -40.7% | -45.3% | +1.5% | +5.6% | +17.2% | +87.9% | |
| Quick Ratio | 11.98 | 12.09 | 12.08 | 12.66 | 11.98 | 10.66 | 10.39 | 14.86 | 13.81 | 17.13 | 14.77 | 10.42 | 8.08 | 8.65 | 5.65 | 7.19 | 6.92 | 9.18 | 9.88 | 12.14 | 12.65 |
| — | +13.4% | +16.2% | -14.8% | -13.2% | -37.7% | -29.7% | +42.6% | +70.9% | +98.1% | +161.4% | +44.9% | +16.7% | -5.8% | -42.8% | -40.7% | -45.3% | +1.5% | +5.6% | +17.2% | +87.9% | |
| Interest Coverage | -1061.17 | -205.87 | -1140.89 | -1262.60 | -330.39 | -1337.52 | -1465.35 | -1213.57 | -1017.29 | -1921.29 | -47.18 | -31.78 | -58.49 | -57.51 | -51.52 | -48.11 | -35.80 | -33.99 | -29.89 | -33.21 | -21.91 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BCYC stock.
Bicycle Therapeutics plc's current P/E is -1.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bicycle Therapeutics plc's current operating margin is -341.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bicycle Therapeutics plc's business trajectory between earnings reports.